{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:16:56Z","timestamp":1792513016410,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 HL64190"],"award-info":[{"award-number":["P01 HL64190"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08 HL 146991-01"],"award-info":[{"award-number":["K08 HL 146991-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ymthe.2020.06.001","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T21:02:19Z","timestamp":1591822939000},"page":"2073-2082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":212,"title":["Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-1559","authenticated-orcid":false,"given":"Lindsey A.","family":"George","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret V.","family":"Ragni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.J.","family":"Rasko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie J.","family":"Raffini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Samelson-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margareth","family":"Ozelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Hazbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa R.","family":"Runowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Wellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Wachtel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier M.","family":"Anguela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudia","family":"Kuranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Mingozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"High","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2020.06.001_bib1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2020.06.001_bib2","doi-asserted-by":"crossref","first-page":"eaan4672","DOI":"10.1126\/science.aan4672","article-title":"Gene therapy comes of age","volume":"359","author":"Dunbar","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.06.001_bib3","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.06.001_bib4","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2020.06.001_bib5","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2020.06.001_bib6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1706910","article-title":"Gene Therapy","volume":"381","author":"High","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.06.001_bib7","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant","volume":"377","author":"George","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.06.001_bib8","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-Factor VIII Gene Transfer in Severe Hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.06.001_bib9","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ymthe.2017.12.009","article-title":"Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice","volume":"26","author":"Bunting","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.06.001_bib10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.06.001_bib11","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jhep.2013.04.004","article-title":"Monogenic diseases that can be cured by liver transplantation","volume":"59","author":"Fagiuoli","year":"2013","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ymthe.2020.06.001_bib12","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3389","article-title":"Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas","volume":"47","author":"Nault","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2020.06.001_bib13","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI79213","article-title":"Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy","volume":"125","author":"Chandler","year":"2015","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2020.06.001_bib14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1126\/science.1142658","article-title":"AAV vector integration sites in mouse hepatocellular carcinoma","volume":"317","author":"Donsante","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.06.001_bib15","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/mt.2016.52","article-title":"Recombinant AAV Integration Is Not Associated With Hepatic Genotoxicity in Nonhuman Primates and Patients","volume":"24","author":"Gil-Farina","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.06.001_bib16","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1182\/blood-2010-08-302729","article-title":"Assessing the potential for AAV vector genotoxicity in a murine model","volume":"117","author":"Li","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.06.001_bib17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/ng1179","article-title":"AAV serotype 2 vectors preferentially integrate into active genes in mice","volume":"34","author":"Nakai","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2020.06.001_bib18","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.06.001_bib19","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.omtm.2019.09.005","article-title":"Enhanced Factor IX Activity following Administration of AAV5-R338L \u201cPadua\u201d Factor IX versus AAV5 WT Human Factor IX in NHPs","volume":"15","author":"Spronck","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.06.001_bib20","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2020.06.001_bib21","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood-2016-02-683169","article-title":"Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project","volume":"129","author":"Manco-Johnson","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.06.001_bib22","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.06.001_bib24","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.06.001_bib25","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/sj.gt.3301541","article-title":"Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors","volume":"8","author":"Donsante","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2020.06.001_bib26","doi-asserted-by":"crossref","first-page":"11264","DOI":"10.1073\/pnas.1117032109","article-title":"Induction of hepatocellular carcinoma by in\u00a0vivo gene targeting","volume":"109","author":"Wang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.06.001_bib27","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1089\/hum.2012.112","article-title":"Recombinant adeno-associated virus integration sites in murine liver after ornithine transcarbamylase gene correction","volume":"24","author":"Zhong","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.06.001_bib28","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood-2008-10-181479","article-title":"Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy","volume":"113","author":"Niemeyer","year":"2009","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.ymthe.2020.06.001_bib29","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/blood-2019-126007","article-title":"Long-Term AAV-Mediated Factor VIII Expression in Nine Hemophilia A Dogs: A 10 Year Follow-up Analysis on Durability, Safety and Vector Integration","volume":"134","author":"Nguyen","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.06.001_bib30","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2011-09-382317","article-title":"Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer","volume":"119","author":"Buchlis","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.06.001_bib31","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ymthe.2005.03.020","article-title":"No evidence for tumorigenesis of AAV vectors in a large-scale study in mice","volume":"12","author":"Bell","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.06.001_bib32","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2015-10-675140","article-title":"Men with severe hemophilia in the United States: birth cohort analysis of a large national database","volume":"127","author":"Mazepa","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.06.001_bib33","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1111\/j.1572-0241.2003.07678.x","article-title":"The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias?","volume":"98","author":"Goodgame","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ymthe.2020.06.001_bib34","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1053\/jhep.2001.27831","article-title":"Estimating progression to cirrhosis in chronic hepatitis C virus infection","volume":"34","author":"Freeman","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2020.06.001_bib35","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.cgh.2016.01.009","article-title":"Serum Biomarkers Indicate Long-term Reduction in Liver Fibrosis in Patients With Sustained Virological Response to Treatment for HCV Infection","volume":"14","author":"Lu","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2020.06.001_bib36","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/hae.13668","article-title":"Incidence and risk factors for hepatocellular cancer in individuals with haemophilia: A National Inpatient Sample Study","volume":"25","author":"Thalappillil","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2020.06.001_bib37","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ymthe.2020.06.001_bib39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/hgtb.2012.243","article-title":"Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy","volume":"24","author":"Louis Jeune","year":"2013","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.ymthe.2020.06.001_bib40","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1089\/hum.2017.094","article-title":"A Retrospective Study of the Cytokine Profile Changes in Mice with FVIII Inhibitor Development After Adeno-Associated Virus-Mediated Gene Therapy in a Hemophilia A Mouse Model","volume":"29","author":"Sun","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.06.001_bib41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/gt.2016.75","article-title":"Direct interaction of human serum proteins with AAV virions to enhance AAV transduction: immediate impact on clinical applications","volume":"24","author":"Wang","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2020.06.001_bib42","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood-2002-10-3296","article-title":"AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B","volume":"101","author":"Manno","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.06.001_bib43","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.omtm.2018.07.011","article-title":"An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs","volume":"10","author":"Sun","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.06.001_bib44","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.06.001_bib45","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/gt.2011.90","article-title":"Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia","volume":"19","author":"Li","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2020.06.001_bib46","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2019.05.014","article-title":"Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors","volume":"14","author":"Kruzik","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.06.001_bib47","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/humc.2016.048","article-title":"AAV Natural Infection Induces Broad Cross-Neutralizing Antibody Responses to Multiple AAV Serotypes in Chimpanzees","volume":"27","author":"Calcedo","year":"2016","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.06.001_bib48","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1089\/hum.2019.143","article-title":"Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome","volume":"30","author":"Aronson","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.06.001_bib49","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/mt.2015.179","article-title":"Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids","volume":"23","author":"Wang","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.06.001_bib50","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/mt.2012.84","article-title":"Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B","volume":"20","author":"Mingozzi","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.06.001_bib51","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1128\/JVI.73.2.1309-1319.1999","article-title":"Cloning and characterization of adeno-associated virus type 5","volume":"73","author":"Chiorini","year":"1999","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2020.06.001_bib52","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1128\/JVI.02710-14","article-title":"Adeno-associated virus serotype 1 (AAV1)- and AAV5-antibody complex structures reveal evolutionary commonalities in parvovirus antigenic reactivity","volume":"89","author":"Tseng","year":"2015","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2020.06.001_bib53","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1089\/hum.2006.17.440","article-title":"Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors","volume":"17","author":"Halbert","year":"2006","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.06.001_bib54","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/gt.2014.47","article-title":"Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors","volume":"21","author":"Liu","year":"2014","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2020.06.001_bib55","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.ymthe.2017.05.003","article-title":"Successful Repeated Hepatic Gene Delivery in Mice and Non-human Primates Achieved by Sequential Administration of AAV5(ch) and AAV1","volume":"25","author":"Majowicz","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.06.001_bib56","unstructured":"US Food and Drug Administration (2006). Guidance for Industry: Gene Therapy Clinical Trials \u2013 Observing Subjects for Delayed Adverse Events, November 2006. https:\/\/www.fda.gov\/media\/72225\/download."},{"key":"10.1016\/j.ymthe.2020.06.001_bib57","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1089\/hgtb.2015.037","article-title":"Determination of anti-adeno-associated virus vector neutralizing antibody titer with an in\u00a0vitro reporter system","volume":"26","author":"Meliani","year":"2015","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.ymthe.2020.06.001_bib58","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1006\/mthe.2000.0075","article-title":"Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in\u00a0vivo but not in\u00a0vitro","volume":"1","author":"Miao","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.06.001_bib59","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1074\/jbc.270.10.5276","article-title":"Role of intron I in expression of the human factor IX gene","volume":"270","author":"Kurachi","year":"1995","journal-title":"J.\u00a0Biol. Chem."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001620302914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001620302914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:57:18Z","timestamp":1761501438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001620302914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1525001620302914"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.06.001","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020","name":"copyright","label":"Copyright"}]}}